261 related articles for article (PubMed ID: 31944367)
21. The Clinical Significance of Perineural Invasion by Prostate Cancer on Needle Core Biopsy: Involvement of Single Versus Multiple Sextant Sites.
Bell PD; Teramoto Y; Gurung PMS; Numbere N; Yang Z; Miyamoto H
Arch Pathol Lab Med; 2022 Oct; 146(10):1252-1257. PubMed ID: 35020791
[TBL] [Abstract][Full Text] [Related]
22. The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance.
Kato M; Hirakawa A; Kobayashi Y; Yamamoto A; Ishida R; Sano T; Kimura T; Majima T; Ishida S; Funahashi Y; Sassa N; Fujita T; Matsukawa Y; Yamamoto T; Hattori R; Gotoh M; Tsuzuki T
Prostate; 2019 Jul; 79(10):1065-1070. PubMed ID: 31025722
[TBL] [Abstract][Full Text] [Related]
23. How Much Reliable Is the Current Belief on Grade Group 1 Prostate Cancer?
Chung MS; Choi YJ; Lee YS; Yoon BI; Ha US
Pathol Oncol Res; 2021; 27():629489. PubMed ID: 34257593
[No Abstract] [Full Text] [Related]
24. Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance.
Balakrishnan AS; Cowan JE; Cooperberg MR; Shinohara K; Nguyen HG; Carroll PR
J Urol; 2019 Sep; 202(3):506-510. PubMed ID: 30958738
[TBL] [Abstract][Full Text] [Related]
25. Prostatic Ductal Adenocarcinoma Controlled for Tumor Grade, Stage, and Margin Status Does Not Independently Influence the Likelihood of Biochemical Recurrence in Localized Prostate Cancer After Radical Prostatectomy.
Kryvenko ON; Iakymenko OA; De Lima Guido LP; Bhattu AS; Merhe A; Mouzannar A; Briski LM; Oymagil I; Lugo I; Nemov I; Ritch CR; Kava BR; Punnen S; Jorda M; Parekh DJ; Gonzalgo ML
Arch Pathol Lab Med; 2022 Aug; 146(8):1012-1017. PubMed ID: 34739539
[TBL] [Abstract][Full Text] [Related]
26. Clinical, Pathological and Oncologic Findings of Radical Prostatectomy with Extraprostatic Extension Diagnosed on Preoperative Prostate Biopsy.
Faisal FA; Tosoian JJ; Han M; Macura KJ; Pavlovich CP; Lotan TL
J Urol; 2019 May; 201(5):937-942. PubMed ID: 30414957
[TBL] [Abstract][Full Text] [Related]
27. Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer.
Kweldam CF; Wildhagen MF; Steyerberg EW; Bangma CH; van der Kwast TH; van Leenders GJ
Mod Pathol; 2015 Mar; 28(3):457-64. PubMed ID: 25189638
[TBL] [Abstract][Full Text] [Related]
28. Impact of Cribriform Pattern and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy.
Tom MC; Nguyen JK; Lucianò R; Mian OY; Stephans KL; Ciezki JP; Smile TD; Wei W; McKenney JK; Magi-Galluzzi C; Tendulkar RD
J Urol; 2019 Oct; 202(4):710-716. PubMed ID: 31059665
[TBL] [Abstract][Full Text] [Related]
29. Downgrading of grade group 2 intermediate-risk prostate cancer from biopsy to radical prostatectomy: Comparison of outcomes and predictors to identify potential candidates for active surveillance.
Su ZT; Patel HD; Epstein JI; Pavlovich CP; Allaf ME
Cancer; 2020 Apr; 126(8):1632-1639. PubMed ID: 32031685
[TBL] [Abstract][Full Text] [Related]
30. Percentage of Gleason pattern 4 and tumor volume predict adverse pathological stage and margin status at radical prostatectomy in grade Group 2 and grade Group 3 prostate cancers.
Iakymenko OA; Lugo I; Briski LM; Nemov I; Punnen S; Kwon D; Pollack A; Stoyanova R; Parekh DJ; Jorda M; Gonzalgo ML; Kryvenko ON
Prostate; 2021 Sep; 81(12):866-873. PubMed ID: 34184782
[TBL] [Abstract][Full Text] [Related]
31. Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer.
Kweldam CF; Kümmerlin IP; Nieboer D; Steyerberg EW; Bangma CH; Incrocci L; van der Kwast TH; Roobol MJ; van Leenders GJ
Mod Pathol; 2017 Aug; 30(8):1126-1132. PubMed ID: 28530220
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy.
Choy B; Pearce SM; Anderson BB; Shalhav AL; Zagaja G; Eggener SE; Paner GP
Am J Surg Pathol; 2016 Oct; 40(10):1400-6. PubMed ID: 27379821
[TBL] [Abstract][Full Text] [Related]
33. Multiparametric MRI prior to radical prostatectomy identifies intraductal and cribriform growth patterns in prostate cancer.
Tonttila PP; Ahtikoski A; Kuisma M; Pääkkö E; Hirvikoski P; Vaarala MH
BJU Int; 2019 Dec; 124(6):992-998. PubMed ID: 31102571
[TBL] [Abstract][Full Text] [Related]
34. Is Grade Group 1 (Gleason score 3 + 3 = 6) adenocarcinoma of the prostate really cancer?
Epstein JI
Curr Opin Urol; 2022 Jan; 32(1):91-95. PubMed ID: 34783714
[TBL] [Abstract][Full Text] [Related]
35. Atypical intraductal proliferation detected in prostate needle biopsy is a marker of unsampled intraductal carcinoma and other adverse pathological features: a prospective clinicopathological study of 62 cases with emphasis on pathological outcomes.
Shah RB; Nguyen JK; Przybycin CG; Reynolds JP; Cox R; Myles J; Klein E; McKenney JK
Histopathology; 2019 Sep; 75(3):346-353. PubMed ID: 31012493
[TBL] [Abstract][Full Text] [Related]
36. Large cribriform glands (> 0.25 mm diameter) as a predictor of adverse pathology in men with Grade Group 2 prostate cancer.
Greenland NY; Cowan JE; Stohr BA; Simko JP; Carroll PR; Chan E
Histopathology; 2024 Mar; 84(4):614-623. PubMed ID: 38012532
[TBL] [Abstract][Full Text] [Related]
37. Increasing age predicts adverse pathology including intraductal carcinoma of the prostate and cribriform patterns in deferred radical prostatectomy after upfront active surveillance for Gleason grade group 1 prostate cancer: analysis of prospective observational study cohort.
Tohi Y; Ishikawa R; Kato T; Miyakawa J; Matsumoto R; Mori K; Mitsuzuka K; Inokuchi J; Matsumura M; Shiga K; Naito H; Kohjimoto Y; Kawamura N; Inoue M; Akamatsu S; Terada N; Miyazawa Y; Narita S; Haba R; Sugimoto M
Jpn J Clin Oncol; 2023 Oct; 53(10):984-990. PubMed ID: 37496400
[TBL] [Abstract][Full Text] [Related]
38. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.
Savdie R; Horvath LG; Benito RP; Rasiah KK; Haynes AM; Chatfield M; Stricker PD; Turner JJ; Delprado W; Henshall SM; Sutherland RL; Kench JG
BJU Int; 2012 Jun; 109(12):1794-800. PubMed ID: 21992536
[TBL] [Abstract][Full Text] [Related]
39. Large and small cribriform architecture have similar adverse clinical outcome on prostate cancer biopsies.
Rijstenberg LL; Hansum T; Kweldam CF; Kümmerlin IP; Remmers S; Roobol MJ; van Leenders GJLH
Histopathology; 2022 Jun; 80(7):1041-1049. PubMed ID: 35384019
[TBL] [Abstract][Full Text] [Related]
40. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
